This is a retatrutide signal, not amplified by MOTS-c, but worth tracking at high reta doses
Quantitative appetite assessments using validated scales demonstrate significant reductions in hunger scores and increases in fullness ratings compared to baseline
Pemvidutide in alcohol-associated liver disease (ALD) Recent Highlights: In May 2026, the company announced that Pemvidutide demonstrated significant metabolic improvements in patients with MASH in new 48week IMPACT Phase 2b data
Now focus on extending hold time toward 3-5 minutes, perfecting the pre-dose fasting routine, and paying attention to how different timing strategies affect your results throughout the day
Clinical trials report an average of 1215% body weight reduction in patients using GLP-1 drugs like Wegovy and Mounjaro
If you know upfront that indefinite treatment is not financially or personally viable, that knowledge should shape your initial goals and your investment in building lifestyle habits during the treatment window
